{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T03:19:20Z","timestamp":1767928760347,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.farma.2025.11.012","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:22:18Z","timestamp":1767907338000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Seguridad de los inhibidores de tirosina cinasa de Bruton en la leucemia linf\u00e1tica cr\u00f3nica: pr\u00e1ctica en vida real"],"prefix":"10.1016","author":[{"given":"Roc\u00edo","family":"Bello-Calvo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Gonz\u00e1lez-Resina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Araceli","family":"Rubio-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itziar","family":"Larrod\u00e9-Leci\u00f1ena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Pilar","family":"Delgado-Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Reyes","family":"Abad-Sazatornil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2025.11.012_bb0005","series-title":"Grupo Espa\u00f1ol de Leucemia Linfoc\u00edtica Cr\u00f3nica (GELLC). Gu\u00eda de pr\u00e1ctica cl\u00ednica para el diagn\u00f3stico y tratamiento de la leucemia linfoc\u00edtica cr\u00f3nica y el linfoma linfoc\u00edtico de c\u00e9lulas peque\u00f1as","year":"2024"},{"issue":"1","key":"10.1016\/j.farma.2025.11.012_bb0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.farma.2025.11.012_bb0015","year":"2016","journal-title":"AEMPS"},{"issue":"3","key":"10.1016\/j.farma.2025.11.012_bb0020","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.farma.2025.11.012_bb0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.farma.2025.11.012_bb0030","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.farma.2025.11.012_bb0035","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1016\/j.clml.2021.07.022","article-title":"Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC STUDY)","volume":"21","author":"Abrisqueta","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"31","key":"10.1016\/j.farma.2025.11.012_bb0040","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.farma.2025.11.012_bb0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.farma.2025.11.012_bb0050","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/cid\/ciy175","article-title":"Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer","volume":"67","author":"Varughese","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.farma.2025.11.012_bb0055","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.farma.2025.11.012_bb0060","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.farma.2025.11.012_bb0065","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/cancers16061228","article-title":"Real-world outcome of treatment with single-agent ibrutinib in italian patients with chronic lymphocytic leukemia: final results of the EVIdeNCE study","volume":"16","author":"Mauro","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.farma.2025.11.012_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1428464","article-title":"Management of infections for patient treated with ibrutinib in clinical practice","volume":"14","author":"Barat\u00e8","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.farma.2025.11.012_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1062376","article-title":"Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia?","volume":"14","author":"Noto","year":"2023","journal-title":"Front Immunol"},{"issue":"26","key":"10.1016\/j.farma.2025.11.012_bb0080","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1182\/blood.2024024667","article-title":"Sustained benefit of zanubrutinib vs ibrutinib in patients with R\/R CLL\/SLL: final comparative analysis of ALPINE","volume":"144","author":"Brown","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.farma.2025.11.012_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.668162","article-title":"Acalabrutinib: a selective bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies","volume":"11","author":"Abbas","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.farma.2025.11.012_bb0090","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase III trial","volume":"41","author":"Hillmen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.farma.2025.11.012_bb0095","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.farma.2025.11.012_bb0100","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.farma.2025.11.012_bb0105","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013 rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325001758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634325001758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:22:21Z","timestamp":1767907341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634325001758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"alternative-id":["S1130634325001758"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2025.11.012","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seguridad de los inhibidores de tirosina cinasa de Bruton en la leucemia linf\u00e1tica cr\u00f3nica: pr\u00e1ctica en vida real","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2025.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}